Delivery Order SPE2DB22D2211-SPE2DB25FSERK
- Not listed
- The Defense Logistics Agency awarded a $13,150.18 delivery order to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pen injectors on September 9, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management, reflecting the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a delivery order valued at $2,971.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-competitive, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management...
- The Defense Logistics Agency awarded a delivery order valued at $31,465.83 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pen injectors on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $26,267.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This is a non-set-aside contract with performance completion targeted for August 18, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management, reflecting the federal government's pharmaceutical procurement needs...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $7,403.76 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. This is a firm fixed-price, non-set-aside contract with a completion date of August 14, 2025, and performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a delivery order valued at $28,363.85 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSERKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $23,996.70 to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. This firm fixed-price delivery order, which is classified as a child contract with no set-aside designation, has an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the federal government's healthcare procurement needs across military and veteran populations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which holds a ceiling value of $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications, vaccines, and medical devices to support Defense Health Agency operations and other government healthcare systems worldwide. The competitively awarded contract demonstrates the vendor's capability to meet federal requirements for specialty pharmaceutical products across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.0k | 9/10/25 |